The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer. Issue 105 (August 2018)

• Record Type: Journal Article
• Authors: Diao, Wei; Tian, Fangfang; Jia, Zhiyun
• Is Part Of: European journal of radiology. Issue 105(2018)
• Page Start: 1
• Page End: 7
• Publication Date: 2018-08
• Subjects: PET/CT positron emission tomography/computed tomography -- 18F-FDG fluorine-18-fluorodeoxyglucose -- BC breast cancer -- IDC invasive ductal carcinoma patients -- EFS event-free survival -- DFS disease-free survival -- HR hazard ratio -- OS overall survival -- SUVmax maximum standardized uptake value -- ALN axillary lymph node; Breast neoplasms -- Prognosis -- SUVmax -- Positron emission tomography/computed tomography -- Meta-analysis; Medical radiology -- Periodicals; Radiology -- Periodicals; Radiologie médicale -- Périodiques; Medical radiology; Periodicals; 616.075705
• DOI: 10.1016/j.ejrad.2018.05.014
• Languages: English
• ISSNs: 0720-048X

Abstract

Highlights: Review of papers from 1993 to April 2018. A total of 3574 breast cancer patients, from 15 studies were included for review. High SUVmax invasive ductal carcinoma patients showed a significant prognostic value. Abstract: Purpose: To evaluate the prognostic value of maximum standardized uptake values (SUVmax ) measured in the primary lesion and axillary lymph nodes (ALN) by pretreatment fluorine-18-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) in patients with breast cancer. Methods: We systematically searched PubMed, Embase, and the Cochrane Library. The primary prognosis endpoint was event-free survival (EFS), and the secondary endpoint was overall survival (OS). The pooled hazard ratio (HR) was estimated by using random-effects model according to the results of heterogeneity. Results: Fifteen eligible studies with 3574 breast cancer patients were included. For EFS, patients with higher primary SUVmax showed a poorer survival prognosis with pooled HR of 1.96 (95% confidence interval (CI) 1.40–2.73). The combined HR of high SUVmax in ALN and ALN-to-primary SUVmax ratio (N/T ratio) were 1.89 (95% CI 0.70–5.07) and 2.06 (95% CI 0.59–7.21), respectively. In analyzing invasive ductal carcinoma (IDC) patients, the pooled HR was 1.91 (95% CI 1.40–2.64). For OS, the pooled HR of SUVmax in primary lesion and ALN were 0.64 (95% CI 0.23–1.84) and 1.09 (95% CI 0.07–16.53), respectively. Conclusions: Our meta-analysis suggested that patients with high primary SUVmax may experience a higher risk for recurrence or a poor progression. Moreover, the SUVmax of 18 F-FDG showed a significant prognostic value in IDC patients.